ATE429431T1 - 2-amino-benzoxazol-suphonamide als breitspektrum- hiv-protease-inhibitoren - Google Patents

2-amino-benzoxazol-suphonamide als breitspektrum- hiv-protease-inhibitoren

Info

Publication number
ATE429431T1
ATE429431T1 AT02735354T AT02735354T ATE429431T1 AT E429431 T1 ATE429431 T1 AT E429431T1 AT 02735354 T AT02735354 T AT 02735354T AT 02735354 T AT02735354 T AT 02735354T AT E429431 T1 ATE429431 T1 AT E429431T1
Authority
AT
Austria
Prior art keywords
suphonamides
spectr
benzoxazole
broad
amino
Prior art date
Application number
AT02735354T
Other languages
English (en)
Inventor
Dominique Surleraux
Sandrine Vendeville
Wim Verschueren
Bethune Marie-Pierre De
Kock Herman De
Abdellah Tahri
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Application granted granted Critical
Publication of ATE429431T1 publication Critical patent/ATE429431T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT02735354T 2001-05-11 2002-05-10 2-amino-benzoxazol-suphonamide als breitspektrum- hiv-protease-inhibitoren ATE429431T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01201732 2001-05-11
PCT/EP2002/005212 WO2002092595A1 (en) 2001-05-11 2002-05-10 Broadspectrum 2-amino-benzoxazole sulfonamide hiv protease inhibitors

Publications (1)

Publication Number Publication Date
ATE429431T1 true ATE429431T1 (de) 2009-05-15

Family

ID=8180286

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02735354T ATE429431T1 (de) 2001-05-11 2002-05-10 2-amino-benzoxazol-suphonamide als breitspektrum- hiv-protease-inhibitoren

Country Status (31)

Country Link
US (2) US7622490B2 (de)
EP (1) EP1387842B1 (de)
JP (1) JP4467889B2 (de)
KR (1) KR100878853B1 (de)
CN (1) CN100549007C (de)
AP (1) AP1652A (de)
AR (1) AR035970A1 (de)
AT (1) ATE429431T1 (de)
AU (1) AU2002310818B2 (de)
BG (1) BG66350B1 (de)
BR (1) BR0209594A (de)
CA (1) CA2444895C (de)
CY (1) CY1109247T1 (de)
CZ (1) CZ304524B6 (de)
DE (1) DE60232067D1 (de)
DK (1) DK1387842T3 (de)
EA (1) EA009590B1 (de)
EE (1) EE05307B1 (de)
ES (1) ES2325809T3 (de)
HR (1) HRP20031026B1 (de)
HU (1) HUP0400438A3 (de)
IL (1) IL158093A0 (de)
MX (1) MXPA03010258A (de)
NO (1) NO326883B1 (de)
NZ (1) NZ529250A (de)
OA (1) OA13134A (de)
PL (1) PL209029B1 (de)
PT (1) PT1387842E (de)
SK (1) SK287952B6 (de)
WO (1) WO2002092595A1 (de)
ZA (1) ZA200307799B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
CA2359945C (en) 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
AU2003202914A1 (en) 2002-01-07 2003-07-24 Sequoia Pharmaceuticals Broad spectrum inhibitors
US7157489B2 (en) 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP4919802B2 (ja) * 2003-09-30 2012-04-18 テイボテク・フアーマシユーチカルズ ベンゾオキサゾールスルホンアミド化合物およびその中間体の製造方法
US8193227B2 (en) 2003-12-11 2012-06-05 Abbott Laboratories HIV protease inhibiting compounds
US20050131042A1 (en) * 2003-12-11 2005-06-16 Flentge Charles A. HIV protease inhibiting compounds
WO2005063770A1 (en) 2003-12-23 2005-07-14 Tibotec Pharmaceuticals Ltd. Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate
ME01059B (me) 2003-12-23 2012-10-20 Janssen Sciences Ireland Uc Proces za pripremanje (3r,3as,6ar)-heksahidrofuro [2,3-b] furan-3-il (1s,2r)-3-[[(4-aminofenil) sulfonil] (izobutil) amino]-1-benzil-2- hidroksipropilkarbamata
EP2422781A1 (de) * 2004-05-07 2012-02-29 Sequoia Pharmaceuticals, Inc. Resistenzabweisende retrovirale Proteaseinhibitoren
RU2421459C2 (ru) 2005-02-25 2011-06-20 Тиботек Фармасьютикалз Лтд. Синтез предшественника ингибитора протеазы
AR053845A1 (es) * 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
US20120220520A1 (en) * 2006-10-17 2012-08-30 Van T Klooster Gerben Albert Eleutherius Bioavailable combinations for hcv treatment
WO2014194519A1 (en) 2013-06-07 2014-12-11 Merck Sharp & Dohme Corp. Imidazole derivatives and methods of use thereof for improving pharmacokinetics of drug

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8204879D0 (sv) 1982-08-26 1982-08-26 Haessle Ab Novel chemical intermediates
EP0445926B1 (de) 1990-03-09 1996-08-21 Milliken Research Corporation Organische Materialien, die sulfonamidogebundene Poly(oxyalkylen)gruppen tragen und ihre Herstellung
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO1994004491A1 (en) * 1992-08-25 1994-03-03 G.D. Searle & Co. N-(alkanoylamino-2-hydroxypropyl)-sulfonamides useful as retroviral protease inhibitors
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
EP0715618B1 (de) * 1993-08-24 1998-12-16 G.D. Searle & Co. Hydroxyaminosulfonamide verwendbar als inhibitoren retroviraler proteasen
SK283569B6 (sk) 1993-10-01 2003-09-11 Astra Aktiebolag Spôsob spracovania jemne deleného práškového liečiva, zariadenie na vykonávanie tohto spôsobu a aglomeráty vyrobené týmto spôsobom
US6143747A (en) 1995-01-20 2000-11-07 G. D. Searle & Co. Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors
US5756533A (en) * 1995-03-10 1998-05-26 G.D. Searle & Co. Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6150556A (en) * 1995-03-10 2000-11-21 G. D. Dearle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US5705500A (en) * 1995-03-10 1998-01-06 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
CN1530372A (zh) 1995-03-10 2004-09-22 G.D.ɪ����˾ 杂环羰基氨基酸羟乙氨基磺酰胺逆转录病毒蛋白酶抑制剂
AU7722296A (en) * 1995-11-15 1997-06-05 G.D. Searle & Co. Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
ATE255883T1 (de) 1996-05-20 2003-12-15 Janssen Pharmaceutica Nv Fungizide mittel mit verbesserter bioverfügbarkeit
JP3608800B2 (ja) 1997-03-26 2005-01-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗真菌剤およびポリマーでコートされたコアを有するペレット剤
GB9717849D0 (en) 1997-08-23 1997-10-29 Seal Sands Chemicals Limited Preparation of pyridene derivatives
AU2012199A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
WO1999033792A2 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
EE200000386A (et) 1997-12-24 2001-12-17 Vertex Pharmaceuticals Incorporated Aspartüülproteaasi inhibiitorite eelravimid
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
WO1999067254A2 (en) * 1998-06-23 1999-12-29 The United States Of America Represented By The Secretary, Department Of Health And Human Services Multi-drug resistant retroviral protease inhibitors and use thereof
PT2336134T (pt) 1998-06-23 2016-10-19 The Board Of Trustees Of The Univ Of Illionis Ensaio de aptidão e métodos para reduzir a resistência do hiv à terapia
AR035819A1 (es) * 2001-04-09 2004-07-14 Tibotec Pharm Ltd 2-(amino sustituido)-benzoxazol sulfonamidas, inhibidoras de la proteasa del hiv, composiciones farmaceuticas que comprenden dichos compuestos, metodo in vitro para inhibir la replicacion retroviral y uso de dichos compuestos en la fabricacion de medicamentos

Also Published As

Publication number Publication date
BG66350B1 (bg) 2013-08-30
CN1507446A (zh) 2004-06-23
ES2325809T3 (es) 2009-09-18
HK1062912A1 (en) 2004-12-03
HRP20031026B1 (hr) 2012-07-31
US20040106661A1 (en) 2004-06-03
JP4467889B2 (ja) 2010-05-26
PT1387842E (pt) 2009-07-20
KR20040022417A (ko) 2004-03-12
AR035970A1 (es) 2004-07-28
EE05307B1 (et) 2010-06-15
SK14902003A3 (sk) 2004-07-07
EP1387842B1 (de) 2009-04-22
AU2002310818B2 (en) 2007-12-13
NO20034988D0 (no) 2003-11-10
ZA200307799B (en) 2005-03-30
CA2444895C (en) 2011-02-15
JP2004534757A (ja) 2004-11-18
HUP0400438A2 (hu) 2004-08-30
EP1387842A1 (de) 2004-02-11
BG108309A (bg) 2004-12-30
HUP0400438A3 (en) 2007-08-28
NO326883B1 (no) 2009-03-09
HRP20031026A2 (en) 2005-10-31
PL366780A1 (en) 2005-02-07
MXPA03010258A (es) 2005-03-07
CZ304524B6 (cs) 2014-06-18
AP1652A (en) 2006-08-11
KR100878853B1 (ko) 2009-01-15
NZ529250A (en) 2005-05-27
CA2444895A1 (en) 2002-11-21
US7863306B2 (en) 2011-01-04
SK287952B6 (sk) 2012-06-04
CZ20033290A3 (cs) 2004-05-12
DE60232067D1 (de) 2009-06-04
CY1109247T1 (el) 2014-07-02
EA200301234A1 (ru) 2004-04-29
BR0209594A (pt) 2004-03-30
AP2003002904A0 (en) 2003-12-31
EA009590B1 (ru) 2008-02-28
DK1387842T3 (da) 2009-08-10
IL158093A0 (en) 2004-03-28
EE200300547A (et) 2004-02-16
CN100549007C (zh) 2009-10-14
PL209029B1 (pl) 2011-07-29
OA13134A (en) 2006-12-13
US7622490B2 (en) 2009-11-24
WO2002092595A1 (en) 2002-11-21
US20100029632A1 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
CY2012007I1 (el) Πεπτιδομιμητικοι αναστολεις πρωτεασης
ATE397925T1 (de) Cis-imidazoline als mdm2-hemmer
DE60234125D1 (de) E inhibitoren
CY2015028I2 (el) Ενας αναστολεας ν-ακυλοσφιγγοσινο γλυκοζυλοτρανσφερασης
NO20034042L (no) Metallproteinase-inhibitorer
PT1370553E (pt) Inibidores de rhoquinase
DE60218138D1 (de) Rho-kinase inhibitoren
EE200300439A (et) Metalloproteinaasi inhibiitorid
EP1499336A4 (de) Proteasehemmer
NO20034032D0 (no) Metallproteinase-inhibitorer
DE60215623D1 (de) Breitspektrum 2-(substituierte-amino)-benzothiazol-sulfonamide hiv protease inhibitoren
DK1458447T3 (da) Kombination af cytokrom-p450-beroende proteasinhibitorer
ATE429431T1 (de) 2-amino-benzoxazol-suphonamide als breitspektrum- hiv-protease-inhibitoren
IS7305A (is) HIV-integrasa tálmar
NO20025786D0 (no) Protaseinhibitorer
NO20043114L (no) Bredspektrede heterocyklisk substituerte fenylinneholdende sulfonamid-HIV-proteaseinhibitorer
NO20025005L (no) Proteaseinhibitorer
EP1463521A4 (de) Gp41-hemmer
NO20013535L (no) Nöytrofil-funksjons-inhibitorer
NO20032328D0 (no) Proteaseinhibitorer
EP1427439A4 (de) Gamma-drei-protease
DE60204623D1 (de) Inhibitor-Schalteranordnung
AU2003287325A8 (en) N-cycloalkylglycines as hiv protease inhibitors
ATE270267T1 (de) Scyphostatin-analoga als smase-inhibitoren
DOP2001000307A (es) Inhibidores de thrombin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1387842

Country of ref document: EP